Author:
Zhou Nian,Tang Lilei,Xie Pingxuan,Miao Ke,Yang Chengjin,Liu Haiyang,Ji Yunheng
Abstract
Abstract
Background
Paris yunnanensis (Melanthiaceae) is a traditional Chinese medicinal plant of significant pharmaceutical importance. Due to previous taxonomic confusion, a congeneric species, Paris liiana, has been mistaken for P. yunnanensis and cultivated on a large scale, leading to the mixing of commercial products (i.e., seedlings and processed rhizomes) of P. yunnanensis with those of P. liiana. This may have adverse effects on quality control in the standardization of P. yunnanensis productions. As the lack of PCR amplifiable genomic DNA within processed rhizomes is an intractable obstacle to the authentication of P. yunnanensis products using PCR-based diagnostic tools, this study aimed to develop a PCR-free method to authenticate commercial P. yunnanensis products, by applying genome skimming to generate complete plastomes and nrDNA arrays for use as the molecular tags.
Results
Based on a dense intraspecies sampling of P. liiana and P. yunnanensis, the robustness of the proposed authentication systems was evaluated by phylogenetic inferences and experimental authentication of commercial seedling and processed rhizome samples. The results indicate that the genetic criteria of both complete plastomes and nrDNA arrays were consistent with the species boundaries to achieve accurate discrimination of P. yunnanensis and P. liinna. Owing to its desirable accuracy and sensitivity, genome skimming can serve as an effective and sensitive tool for monitoring and controlling the trade of P. yunnanensis products.
Conclusion
This study provides a new way to solve the long-standing problem of the molecular authentication of processed plant products due to the lack of PCR amplifiable genomic DNA. The proposed authentication system will support quality control in the standardization of P. yunnanensis products in cultivation and drug production. This study also provides molecular evidence to clarify the long-standing taxonomic confusion regarding the species delimitation of P. yunnanensis, which will contribute to the rational exploration and conservation of the species.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference85 articles.
1. China Pharmacopoeia Committee. Pharmacopoeia of the people’s Republic of China. Sec I, the 2020 edition. Beijing:China Medical Science Press; 2020.
2. Ji Y. A monograph of Paris. Beijing and Singapore: Science Press and Springer; 2021.
3. Li H, Su B, Zhang ZY, et al. An assessment on the rarely medical Paris plants in China with exploring the future development of its plantation. J West China For Sci. 2015a;44:1–6. https://doi.org/10.16473/j.cnki.xblykx1972.2015.03.001.
4. Ding YG, Zhao YL, Zhang J, et al. The traditional uses, phytochemistry, and pharmacological properties of Paris L. (Liliaceae): a review. J Ethnopharmacol. 2021;278:114293. https://doi.org/10.1016/j.jep.2021.114293.
5. Huang LQ, Xiao PG, Wnag YY. Investigation on resources of rare and endangered medicinal plants in China. Shanghai: Shanghai Science and Technology Press; 2012.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献